Scholarlink

Background <p><i>Apolipoprotein E</i> ε4 (<i>APOE4</i>) is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD). A recent case report identified a rare variant in APOE, <i>APOE3</i>-R136S (Christchurch), proposed to confer resistance to autosomal dominant Alzheimer’s Disease (AD). However, it remains unclear whether and how this variant exerts its protective effects.</p> Methods <p>We introduced the R136S variant into mouse <i>Apoe</i> (<i>ApoeCh</i>) and investigated its effect on the development of AD-related pathology using the 5xFAD model of amyloidosis and the PS19 model of tauopathy. We used immunohistochemical and biochemical analysis along with single-cell spatial omics and bulk proteomics to explore the impact of the <i>ApoeCh</i> variant on AD pathological development and the brain’s response to plaques and tau.</p> Results <p>In 5xFAD mice, <i>ApoeCh</i> enhances a Disease-Associated Microglia (DAM) phenotype in microglia surrounding plaques, and reduces plaque load, dystrophic neurites, and plasma neurofilament light chain. By contrast, in PS19 mice, <i>ApoeCh</i> suppresses the microglial and astrocytic responses to tau-laden neurons and does not reduce tau accumulation or phosphorylation, but partially rescues tau-induced synaptic and myelin loss. We compared how microglia responses differ between the two mouse models to elucidate the distinct DAM signatures induced by <i>ApoeCh</i>. We identified upregulation of antigen presentation-related genes in the DAM response in a PS19 compared to a 5xFAD background, suggesting a differential response to amyloid versus tau pathology that is modulated by the presence of <i>ApoeCh</i>. Bulk proteomics show upregulated mitochondrial protein abundance with <i>ApoeCh</i> in 5xFAD mice, but reductions in mitochondrial and translation associated proteins in PS19 mice.</p> Conclusions <p>These findings highlight the ability of the <i>ApoeCh</i> variant to modulate microglial responses based on the type of pathology, enhancing DAM reactivity in amyloid models and dampening neuroinflammation to promote protection in tau models. This suggests that the Christchurch variant's protective effects likely involve multiple mechanisms, including changes in receptor binding and microglial programming.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月22日

查看全文
  • Kristine M. Tran,
  • Nellie E. Kwang,
  • Claire A. Butler,
  • Angela Gomez-Arboledas,
  • Shimako Kawauchi,
  • Cassandra Mar,
  • Donna Chao,
  • Rocio A. Barahona,
  • Celia Da Cunha,
  • Kate I. Tsourmas,
  • Zechuan Shi,
  • Shuling Wang,
  • Sherilyn Collins,
  • Amber Walker,
  • Kai-Xuan Shi,
  • Joshua A. Alcantara,
  • Jonathan Neumann,
  • Duc M. Duong,
  • Nicholas T. Seyfried,
  • Andrea J. Tenner,
  • Frank M. LaFerla,
  • Lindsay A. Hohsfield,
  • Vivek Swarup,
  • Grant R. MacGregor,
  • Kim N. Green

摘要

Background

Apolipoprotein E ε4 (APOE4) is the strongest genetic risk factor for late-onset Alzheimer’s disease (LOAD). A recent case report identified a rare variant in APOE, APOE3-R136S (Christchurch), proposed to confer resistance to autosomal dominant Alzheimer’s Disease (AD). However, it remains unclear whether and how this variant exerts its protective effects.

Methods

We introduced the R136S variant into mouse Apoe (ApoeCh) and investigated its effect on the development of AD-related pathology using the 5xFAD model of amyloidosis and the PS19 model of tauopathy. We used immunohistochemical and biochemical analysis along with single-cell spatial omics and bulk proteomics to explore the impact of the ApoeCh variant on AD pathological development and the brain’s response to plaques and tau.

Results

In 5xFAD mice, ApoeCh enhances a Disease-Associated Microglia (DAM) phenotype in microglia surrounding plaques, and reduces plaque load, dystrophic neurites, and plasma neurofilament light chain. By contrast, in PS19 mice, ApoeCh suppresses the microglial and astrocytic responses to tau-laden neurons and does not reduce tau accumulation or phosphorylation, but partially rescues tau-induced synaptic and myelin loss. We compared how microglia responses differ between the two mouse models to elucidate the distinct DAM signatures induced by ApoeCh. We identified upregulation of antigen presentation-related genes in the DAM response in a PS19 compared to a 5xFAD background, suggesting a differential response to amyloid versus tau pathology that is modulated by the presence of ApoeCh. Bulk proteomics show upregulated mitochondrial protein abundance with ApoeCh in 5xFAD mice, but reductions in mitochondrial and translation associated proteins in PS19 mice.

Conclusions

These findings highlight the ability of the ApoeCh variant to modulate microglial responses based on the type of pathology, enhancing DAM reactivity in amyloid models and dampening neuroinflammation to promote protection in tau models. This suggests that the Christchurch variant's protective effects likely involve multiple mechanisms, including changes in receptor binding and microglial programming.

Graphical Abstract